Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 2
1972 1
1973 1
1974 1
1975 2
1976 2
1977 2
1978 3
1979 2
1980 1
1981 2
1986 1
1988 5
1989 1
1990 1
1991 4
1992 6
1993 4
1994 9
1995 9
1996 11
1997 7
1998 6
1999 5
2000 7
2001 16
2002 6
2003 8
2004 3
2005 3
2006 1
2007 1
2008 2
2009 2
2010 3
2011 3
2012 9
2013 6
2014 4
2015 6
2016 5
2017 3
2018 7
2019 11
2020 9
2021 3
2022 5
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

214 results

Results by year

Filters applied: . Clear all
Page 1
Bispecific antibodies.
Brinkmann U, Kontermann RE. Brinkmann U, et al. Science. 2021 May 28;372(6545):916-917. doi: 10.1126/science.abg1209. Science. 2021. PMID: 34045345 No abstract available.
The making of bispecific antibodies.
Brinkmann U, Kontermann RE. Brinkmann U, et al. MAbs. 2017 Feb/Mar;9(2):182-212. doi: 10.1080/19420862.2016.1268307. MAbs. 2017. PMID: 28071970 Free PMC article. Review.
The present and future of bispecific antibodies for cancer therapy.
Klein C, Brinkmann U, Reichert JM, Kontermann RE. Klein C, et al. Among authors: brinkmann u. Nat Rev Drug Discov. 2024 Apr;23(4):301-319. doi: 10.1038/s41573-024-00896-6. Epub 2024 Mar 6. Nat Rev Drug Discov. 2024. PMID: 38448606 Review.
Bispecific antibodies.
Kontermann RE, Brinkmann U. Kontermann RE, et al. Among authors: brinkmann u. Drug Discov Today. 2015 Jul;20(7):838-47. doi: 10.1016/j.drudis.2015.02.008. Epub 2015 Feb 26. Drug Discov Today. 2015. PMID: 25728220 Free article. Review.
Recombinant immunotoxins.
Pastan I, Pai LH, Brinkmann U, FitzGerald D. Pastan I, et al. Among authors: brinkmann u. Breast Cancer Res Treat. 1996;38(1):3-9. doi: 10.1007/BF01803778. Breast Cancer Res Treat. 1996. PMID: 8825117 Review.
Engineering therapeutic bispecific antibodies using CrossMab technology.
Klein C, Schaefer W, Regula JT, Dumontet C, Brinkmann U, Bacac M, Umaña P. Klein C, et al. Among authors: brinkmann u. Methods. 2019 Feb 1;154:21-31. doi: 10.1016/j.ymeth.2018.11.008. Epub 2018 Nov 16. Methods. 2019. PMID: 30453028 Free article. Review.
Tumor-antigen-binding bispecific antibodies for cancer treatment.
Weidle UH, Kontermann RE, Brinkmann U. Weidle UH, et al. Among authors: brinkmann u. Semin Oncol. 2014 Oct;41(5):653-60. doi: 10.1053/j.seminoncol.2014.08.004. Epub 2014 Aug 12. Semin Oncol. 2014. PMID: 25440609 Free article. Review.
Immunotoxins against cancer.
Brinkmann U, Pastan I. Brinkmann U, et al. Biochim Biophys Acta. 1994 May 27;1198(1):27-45. doi: 10.1016/0304-419x(94)90004-3. Biochim Biophys Acta. 1994. PMID: 8199194 Review. No abstract available.
214 results